Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,304 | 0,308 | 10:29 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.08. | XFRA 7PO: WIEDERAUFNAHME/RESUMPTION | 178 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
08.08. | Poxel SA: Poxel Announces the Opening of Reorganization Proceedings | 333 | Business Wire | POXEL shares to resume trading on August 11, 2025 at market opening
Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative... ► Artikel lesen | |
01.08. | Poxel SA: Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance | 435 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
30.07. | XFRA 7PO: AUSSETZUNG/SUSPENSION | 282 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPOXEL S.A. EO -... ► Artikel lesen | |
POXEL Aktie jetzt für 0€ handeln | |||||
29.07. | Poxel SA: Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading | 493 | Business Wire | Since the rejection of key financial delegations during its Shareholders General Meeting of February 11, 2025, triggering a case of default of certain of its existing debts, Poxel's management... ► Artikel lesen | |
30.06. | Poxel SA: Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update | 362 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
19.06. | Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference | 294 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
28.05. | POXEL SA: New Clinical and Scientific Data on TWYMEEG to be Presented at the 68th Annual Meeting of the Japan Diabetes Society | 441 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
26.05. | Poxel SA: Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 | 447 | Business Wire | PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart Presentation of detailed results... ► Artikel lesen | |
13.05. | Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update | 317 | Business Wire | TWYMEEG consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3 Sumitomo Pharma... ► Artikel lesen | |
16.04. | POXEL SA: Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results | 579 | Business Wire | Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company's... ► Artikel lesen | |
08.04. | POXEL SA: Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG Package Insert to Include Type 2 Diabetes Patients with Renal Impairment | 645 | Business Wire | Approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enables TWYMEEG (Imeglimin) to be prescribed to type-2 diabetic patients with moderate to severe renal impairment. This... ► Artikel lesen | |
31.03. | Poxel SA: Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment | 452 | Business Wire | Newly granted patent covers Imeglimin's use in type-2 diabetic patients with renal impairment and has a patent term in Japan until 2039 This patent further supports Poxel's strategy to... ► Artikel lesen | |
20.03. | Poxel SA: Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy | 529 | Business Wire | Hypertrophic cardiomyopathy (HCM) is the most common human genetic cardiac disorder and can lead to serious complications including heart failure and sudden cardiac death The preclinical... ► Artikel lesen | |
19.02. | POXEL SA: Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook | 885 | Business Wire | Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation... ► Artikel lesen | |
11.02. | POXEL SA: Poxel Announces Results of its Combined General Meeting Held on February 11, 2025 | 504 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
31.01. | POXEL SA: Poxel's partner Sumitomo Pharma reports TWYMEEG gross sales in Japan for Q4 2024 and FY 2024 sales forecast | 766 | Business Wire | TWYMEEG sales continued to increase in Japan for the last quarter 2024 (October-December) by 17% over the prior quarter and by 154% over Q4 2023 TWYMEEG's FY 20241 revised forecast2 of... ► Artikel lesen | |
23.01. | Poxel SA: Poxel Announces its Financial Calendar for 2025 | 471 | Business Wire | Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology... ► Artikel lesen | |
21.01. | Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025 | 468 | Business Wire | Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents Poxel announces the addition of a new... ► Artikel lesen | |
20.01. | Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment | 449 | Business Wire | Patent life covering Imeglimin in China extended to 2039 Ongoing partnership discussions to develop and market Imeglimin in China, the world's second largest type 2 diabetes market
Regulatory... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 86,65 | +0,17 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
EVOTEC | 5,804 | +0,24 % | Evotec Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
MEDIGENE | 0,073 | -1,61 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
BB BIOTECH | 35,750 | +0,28 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
CUREVAC | 4,560 | -0,74 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
MODERNA | 20,850 | +0,26 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
PAION | 0,013 | -50,00 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
VALNEVA | 3,640 | +3,12 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
EPIGENOMICS | 0,870 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
NOVAVAX | 6,506 | +0,23 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
BIOFRONTERA | 2,510 | -3,09 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Biofrontera AG: Biofrontera AG: Neue Prognose
Leverkusen (pta000/01.08.2025/12:00... ► Artikel lesen | |
BIOGEN | 119,55 | -0,25 % | Biogen: Darum ist die Aktie heute der Top-Gewinner in den USA | Der September startet an den US-Börsen holprig - alle großen Indizes notieren klar im Minus. Allerdings gibt es auch heute Aktien, die sich dem Trend widersetzen. Zu den größten Gewinnern gehört der... ► Artikel lesen | |
HEIDELBERG PHARMA | 3,300 | +5,10 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Finanzierung
Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx... ► Artikel lesen | |
NANOREPRO | 1,820 | -2,93 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
4SC | 0,650 | -4,41 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen |